1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - NIH ProtIG Seminar: Proteomics as a Tool to Identify Biomarkers and Therapeutic Targets for Dementia"}],["$","meta","1",{"name":"description","content":"The plasma proteomic changes that precede the onset of dementia and Alzheimer’s disease could yield insights into disease biology and highlight new biomarkers and avenues for intervention. This presentation will demonstrate how proteins measured in blood decades before dementia onset can be combined with genetic data to (1) identify novel early biomarkers for dementia, Alzheimer’s disease, and brain MRI characteristics indicative of cerebral small vessel disease, and (2) better understand the molecular pathways altered in the preclinical and prodromal phase of neurodegenerative disease. This presentation will also illustrate how protein based risk score can be used to enhance our understanding of how health characteristics and subclinical disease states influence brain aging and development of neurodegenerative disease.

For more information go to https://proteome.nih.gov/"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - NIH ProtIG Seminar: Proteomics as a Tool to Identify Biomarkers and Therapeutic Targets for Dementia"}],["$","meta","4",{"property":"og:description","content":"The plasma proteomic changes that precede the onset of dementia and Alzheimer’s disease could yield insights into disease biology and highlight new biomarkers and avenues for intervention. This presentation will demonstrate how proteins measured in blood decades before dementia onset can be combined with genetic data to (1) identify novel early biomarkers for dementia, Alzheimer’s disease, and brain MRI characteristics indicative of cerebral small vessel disease, and (2) better understand the molecular pathways altered in the preclinical and prodromal phase of neurodegenerative disease. This presentation will also illustrate how protein based risk score can be used to enhance our understanding of how health characteristics and subclinical disease states influence brain aging and development of neurodegenerative disease.

For more information go to https://proteome.nih.gov/"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/d3e0fb1b-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/9949a982-bc88-45bc-aa25-2e3373651e78.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - NIH ProtIG Seminar: Proteomics as a Tool to Identify Biomarkers and Therapeutic Targets for Dementia"}],["$","meta","11",{"name":"twitter:description","content":"The plasma proteomic changes that precede the onset of dementia and Alzheimer’s disease could yield insights into disease biology and highlight new biomarkers and avenues for intervention. This presentation will demonstrate how proteins measured in blood decades before dementia onset can be combined with genetic data to (1) identify novel early biomarkers for dementia, Alzheimer’s disease, and brain MRI characteristics indicative of cerebral small vessel disease, and (2) better understand the molecular pathways altered in the preclinical and prodromal phase of neurodegenerative disease. This presentation will also illustrate how protein based risk score can be used to enhance our understanding of how health characteristics and subclinical disease states influence brain aging and development of neurodegenerative disease.

For more information go to https://proteome.nih.gov/"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}